A panel of federal health advisers on Thursday narrowly recommended easing access to several peptides popular with wellness influencers and celebrities, despite warnings from government scientists that the chemicals haven’t been shown to be safe or effective.
In a series of votes, outside experts to the Food and Drug Administration advised the agency to drop current restrictions barring pharmacies from producing injectable peptides with names including BPC-157, TB-500 and KPV.
The panel’s vote is not binding but is likely to embolden Health Secretary Robert F. Kennedy Jr., who has described himself as a “big fan” of peptides and vowed to overturn FDA restrictions put in place under President Joe Biden.
Across several votes, the panelists voted 8-6, with one abstention, in favor of putting the peptides on FDA’s list of substances considered safe for pharmacy compounding. If FDA follows that advice, telehealth companies are expected to ramp up marketing of the chemicals for wellness and cosmetic uses.
Thursday’s vote tally reflected the unusual makeup of the panel. Prior to the meeting, more than a half-dozen people with connections to the peptide industry were added to the group, including doctors, pharmacists or consultants who work in the field.
